280 related articles for article (PubMed ID: 22010128)
1. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study.
Li DK; Yang C; Andrade S; Tavares V; Ferber JR
BMJ; 2011 Oct; 343():d5931. PubMed ID: 22010128
[TBL] [Abstract][Full Text] [Related]
2. Major congenital malformations after first-trimester exposure to ACE inhibitors.
Cooper WO; Hernandez-Diaz S; Arbogast PG; Dudley JA; Dyer S; Gideon PS; Hall K; Ray WA
N Engl J Med; 2006 Jun; 354(23):2443-51. PubMed ID: 16760444
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of increased congenital malformations after first trimester exposures to angiotensin-converting enzyme inhibitors.
Cooper WO
J Cardiovasc Nurs; 2008; 23(1):20-4. PubMed ID: 18158502
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-Converting Enzyme Inhibitors and the Risk of Congenital Malformations.
Bateman BT; Patorno E; Desai RJ; Seely EW; Mogun H; Dejene SZ; Fischer MA; Friedman AM; Hernandez-Diaz S; Huybrechts KF
Obstet Gynecol; 2017 Jan; 129(1):174-184. PubMed ID: 27926639
[TBL] [Abstract][Full Text] [Related]
5. Increased risk of major congenital malformations in early pregnancy use of angiotensin-converting-enzyme inhibitors and angiotensin-receptor-blockers: a meta-analysis.
Fu J; Tomlinson G; Feig DS
Diabetes Metab Res Rev; 2021 Nov; 37(8):e3453. PubMed ID: 33779043
[TBL] [Abstract][Full Text] [Related]
6. [The use of angiotensin converting enzyme (ACE) inhibitors during pregnancy clearly increases the risk of congenital malformations].
de Leeuw PW
Ned Tijdschr Geneeskd; 2006 Jul; 150(29):1605-7. PubMed ID: 16901062
[TBL] [Abstract][Full Text] [Related]
7. Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers.
Walfisch A; Al-maawali A; Moretti ME; Nickel C; Koren G
J Obstet Gynaecol; 2011 Aug; 31(6):465-72. PubMed ID: 21823839
[TBL] [Abstract][Full Text] [Related]
8. Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring.
Huybrechts KF; Hernández-Díaz S; Straub L; Gray KJ; Zhu Y; Patorno E; Desai RJ; Mogun H; Bateman BT
JAMA; 2018 Dec; 320(23):2429-2437. PubMed ID: 30561479
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity.
Schaefer C
Birth Defects Res A Clin Mol Teratol; 2003 Aug; 67(8):591-4. PubMed ID: 14632309
[TBL] [Abstract][Full Text] [Related]
10. [Inhibition of the renin angiotensin system in pregnancy and risk of fetal malformations].
Lonati C; Morganti A
Pediatr Med Chir; 2009; 31(3):137-9. PubMed ID: 19739495
[No Abstract] [Full Text] [Related]
11. Risk of major congenital malformations associated with first-trimester antihypertensives, including amlodipine and methyldopa: A large claims database study 2010-2019.
Ishikawa T; Nishigori H; Akazawa M; Miyakoda K; Noda A; Ishikuro M; Metoki H; Iwama N; Saito M; Sugawara J; Kawame H; Yaegashi N; Kuriyama S; Mano N; Obara T
Pregnancy Hypertens; 2023 Mar; 31():73-83. PubMed ID: 36646019
[TBL] [Abstract][Full Text] [Related]
12. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage.
Bérard A; Ramos E; Rey E; Blais L; St-André M; Oraichi D
Birth Defects Res B Dev Reprod Toxicol; 2007 Feb; 80(1):18-27. PubMed ID: 17187388
[TBL] [Abstract][Full Text] [Related]
13. Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
Diav-Citrin O; Shechtman S; Halberstadt Y; Finkel-Pekarsky V; Wajnberg R; Arnon J; Di Gianantonio E; Clementi M; Ornoy A
Reprod Toxicol; 2011 May; 31(4):540-5. PubMed ID: 21338666
[TBL] [Abstract][Full Text] [Related]
14. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants.
Lennestål R; Otterblad Olausson P; Källén B
Eur J Clin Pharmacol; 2009 Jun; 65(6):615-25. PubMed ID: 19198819
[TBL] [Abstract][Full Text] [Related]
15. β-Blocker Use in Pregnancy and the Risk for Congenital Malformations: An International Cohort Study.
Bateman BT; Heide-Jørgensen U; Einarsdóttir K; Engeland A; Furu K; Gissler M; Hernandez-Diaz S; Kieler H; Lahesmaa-Korpinen AM; Mogun H; Nørgaard M; Reutfors J; Selmer R; Huybrechts KF; Zoega H
Ann Intern Med; 2018 Nov; 169(10):665-673. PubMed ID: 30326014
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: risks versus benefits.
Pucci M; Sarween N; Knox E; Lipkin G; Martin U
Expert Rev Clin Pharmacol; 2015 Mar; 8(2):221-31. PubMed ID: 25612630
[TBL] [Abstract][Full Text] [Related]
17. Adverse pregnancy outcomes associated with first-trimester exposure to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers: A systematic review and meta-analysis.
Buawangpong N; Teekachunhatean S; Koonrungsesomboon N
Pharmacol Res Perspect; 2020 Oct; 8(5):e00644. PubMed ID: 32815286
[TBL] [Abstract][Full Text] [Related]
18. ACE inhibitors and major congenital malformations.
Scialli AR; Lione A
N Engl J Med; 2006 Sep; 355(12):1280; author reply 1281. PubMed ID: 16998965
[No Abstract] [Full Text] [Related]
19. Increased rate of birth defects after first trimester use of angiotensin converting enzyme inhibitors - Treatment or hypertension related? An observational cohort study.
Hoeltzenbein M; Tissen-Diabaté T; Fietz AK; Zinke S; Kayser A; Meister R; Weber-Schoendorfer C; Schaefer C
Pregnancy Hypertens; 2018 Jul; 13():65-71. PubMed ID: 30177074
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin converting enzyme inhibitors in pregnancy.
Mastrobattista JM
Semin Perinatol; 1997 Apr; 21(2):124-34. PubMed ID: 9201818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
